Loading...
Immunotherapies & Innovations for Infectious Diseases Congress 2024

November 27-28 2024 Lyon, France

Program 2023

Day 1

Wednesday, November 22nd 2023

9h30

Registration & Welcome coffee

10h00

Welcome Address

10h05

Opening lectures - Lima & Mexico room

Chaired by Daniel Larocque, Sanofi

CEPI's approach to vaccine libraries and rapid response platforms - an integral part to its 100 Days Mission
CEPI Martina Ochs

Martina Ochs
Project Leader
CEPI, Norway

Title to be defined
Africa CDC Sofonias Kifle Tessema

Sofonias Kifle Tessema
Program lead for pathogen genomics
Africa CDC, Ethiopia

Trained immunity: from pathophysiology to therapeutic target
Radboud University Medical Center Mihai Netea

Mihai Netea
Head of the division of Experimental Medicine
Radboud University Medical Center, Netherlands

11h35

France2030 initiatives - Lima & Mexico room

Accelerating innovation in the field of emerging diseases: the “Biocluster Français pour l'Innovation en Infectiologie (BCF2I)” project
Hospices Civils de Lyon Bruno Lina

Bruno Lina
Head of Department
Laboratoire de Virologie, Centre national de référence virus des infections respiratoires & Centre national de référence entérovirus et parechovirus, France

Developing innovative therapies to cure hepatitis B virus infections: from basic science to clinical applications
Hospices Civils de Lyon Fabien Zoulim

Fabien Zoulim
Head of the Hepatology Department
Hospices Civils de Lyon & Head of the Viral Hepatitis Research Laboratory - INSERM Unit 1052 - France

12h15

Lunch - Poster presentation - B2B - Exhibition Hall

14h00

Track 1: Alternatives to current antibiotics - Lima & Mexico room

Chaired by Sébastien Coyne, Aurobac Therapeutics and Ana Antunes, MabDesign

Challenges of phage therapy in 2023: shared insights from key French private and public players
Hospices Civils de Lyon Frédéric Laurent

Frédéric Laurent
Co-principal investigator
Hospices Civils de Lyon, Centre International de Recherche en Infectiologie Inserm U1111-UMR CNRS 5308, ISPB Lyon - Université Lyon 1, France

Phaxiam Cindy Fèvre

Cindy Fèvre
Scientific director
Phaxiam, France

In situ targeted mutagenesis of gut bacteria
Eligo David Bikard

David Bikard
Head of lab
Pasteur Institute, France
Founder
Eligo Bioscience - France

Incentivizing Novelty in Antibiotic Development
ESSEC Business School Gosia Majewska

Gosia Majewska
Health and industrial organization economist
ESSEC Business School, France

ENABLE-2: A European Antibacterial Drug Discovery Platform
Uppsala University Anders Karlén

Anders Karlén
Project coordinator
ENABLE-2
Head of the Department of Medicinal Chemistry
Uppsala University, Sweden

PanHunter - an all-in-one omics data analysis platform
Evotec Erik Schliep

Erik Schliep
Product Manager
Evotec, France

15h40

Coffee break - B2B - Exhibition Hall - Poster presentation

16h20

Track 2: Immunotherapies - Lima room

Chaired by Geneviève Inchauspé, Transgene

Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis
Francis Crick Institute Anne O'Garra

Anne O'Garra
Principal Group Leader
Francis Crick Institute, UK

Monoclonal antibodies for prolonged Covid-19 protection in immunocompromised individuals
AstraZeneca Cécile Artaud

Cécile Artaud
Therapeutic Area Medical Lead
AstraZeneca, France

Life saving stem cell therapy for septic shock and ARDS
StemInov Julie Hutin

Julie Hutin
Co Founder and CEO
StemInov, France

Securing the supply chain for vaccine adjuvants in the future
Croda Dennis Christensen

Dennis Christensen
Head of Global R&D
Croda, Danmark

Promega: A Partner for Multidisciplinary Infectious Disease Research and Development
Promega Aymeric Morlé

Aymeric Morlé
Custom/OEM specialist
Promega

Accelerating drug discovery using advanced protein and an-tibody development platforms
Sino Biological Yu-Chih Lin

Yu-Chih Lin
Technical Specialist
Sino Biological, Germany

16h20

Workshop - Mexico room

Translational in vivo imaging for anti-infectious diseases treatment and diagnosis follow up by PASREL-Imagerie
PASREL-Imagerie Ali Aït-Ikhlef

Ali Aït-Ikhlef
Business Development Manager
PASREL-Imagerie

PASREL-Imagerie Benoît Delache

Benoît Delache
R&D engineer in animal experimentation
PASREL-Imagerie

PASREL-Imagerie Julien Lemaitre

Julien Lemaitre
Clinical veterinarian and Immunologist
PASREL-Imagerie

17h20

Breakthrough Innovation session - Mexico room

Chaired by Mélanie Denizot, Lyonbiopôle

System serology approach on COVID-19 patients' sera reveal specific immune pattern in the heterogeneous population: The COVIDAuRA study
Hospices Civils de Lyon and Centre International de Recherche Carla Saade

Carla Saade
Phd student
Hospices Civils de Lyon and Centre International de Recherche, France

Fully automated workflow for cytometry data analysis: Evaluating the effects of adjuvant candidates on memory B and T cells in a phase I clinical trial.
Altrabio Julien Nourikyan

Julien Nourikyan
Business Development and Partnerships Manager
Altrabio, France

Limitations of threshold-based decisions in Disease X vaccine clinical trials
Epimod Julien Flaig

Julien Flaig
Epidemiological and health economic simulation modeling
Epimod, France

18h00

Poster presentation - Exhibition Hall - Wine & Cheese

Day 2

Thursday, November 23nd 2023

9h00

Welcome coffee

9h30

Keynote lectures - Lima & Mexico room

Chaired by Daniel Larocque, Sanofi

Opportunities and Challenges of AI for Infectious Disease Vaccines and Therapeutics
Sanofi Saranya Sridhar

Saranya Sridhar
Global Head of Clinical Franchise for the mRNA Center and Head of Translational Medicine
Sanofi, United Kingdom

10h30

Coffee break - B2B - Exhibition Hall - Poster presentation

11h00

Track 3: Diagnostic, prognostic and clinical biomarkers - Lima room

Chaired by Jean François Llitjos, bioMérieux

Biomarkers and AI to develop personalised medicine in sepsis.
Imperial College London Anthony Gordon

Anthony Gordon
Chair in Anaesthesia and Critical Care, NIHR Research Professor & Senior Investigator
Imperial College London, United Kingdom

Endocan, a novel biomarker for pneumonia
Biothelis Philippe Lassale

Philippe Lassale
Founder
Biothelis, France

Advancing anti-viral and vaccine research with Revvity's fluorescent assays
Revvity Mathis Laffenetre

Mathis Laffenetre
LifeScience Product Leader
Revvity, France

A unique solution for antigens that cannot be detected with classical ELISA in medical diagnostic applications: example for inclusion in clinical trial on long COVID.
GeNeuro Hervé Perron

Hervé Perron
Chief Scientific Officer
GeNeuro SA, Switzerland

11h00

Roundtable: EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access - Mexico room

Animated by Nadia Khelef, National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats

GAVI Marta Tufet Bayona

Marta Tufet Bayona
Head of Policy
GAVI, Switzerland

IVI Anh Wartel

Anh Wartel
Deputy Director General / Head
IVI Europe Regional Office (IERO) - Sweden

HERA Bangin Brim

Bangin Brim
Policy Officer Health Threats
European Commission - European Health Emergency Preparedness and Response Authority (HERA), Belgium

IHI Tek-Ang Lim

Tek-Ang Lim
Scientific officer
Innovative Health Initiative (IHI) - Belgium

12h00

Lunch - Poster presentation - B2B - Exhibition Hall

14h00

Track 3: Diagnostic, prognostic and clinical biomarkers - Lima room

Chaired by Cyril Guyard, Bioaster

Identification by proteomics of infection markers in the skin: application to a direct diagnosis of Lyme borreliosis
Université de Strasbourg Nathalie Boulanger

Nathalie Boulanger
Medical entomologist & Research group leader
Université de Strasbourg, France

Strategic Partnerships to Address Diagnostic Unmet Needs in Low- and Middle-Income Countries
BIOASTER Philippe Leissner

Philippe Leissner
Head of R&D Diagnostic Programme
BIOASTER, France

Immune profiling of COVID-19 mRNA vaccines in immunocompromised patients
University of Geneva Arnaud Didierlaurent

Arnaud Didierlaurent
Professor at the Faculty of Medicine
University of Geneva, Switzerland

14h00

Breakthrough Innovation session - Mexico room

Chaired by Fabienne Venet, Hospices Civils de Lyon and Mélanie Denizot, Lyonbiopôle

GlycoFlu, a first-in-class synthetic multivalent sialoside compound with antiviral activity to prevent or treat infections by Influenza viruses
AIS biotech Aurélie Juhem

Aurélie Juhem
Chief Executive Officer
AIS biotech, France

Neutralizing and Enhancing Monoclonal Antibodies in SARS-CoV-2 Convalescent Patients: Lessons from Early Variant Infection and Impact on Shaping Emerging Variants
Hospices Civils of Lyon Frédéric Coutant

Frédéric Coutant
Associate Professor in Immunology
Hospices Civils of Lyon, France

Inhalable Nanofitin as new therapeutic for direct application in respiratory tract
Affilogic Sébastien Viollet

Sébastien Viollet
Scientist
Affilogic, France

New rapid detection of beta-lactamase producing bacteria using fluorogenic probes
Molsid Didier Filopon

Didier Filopon
R&D projects manager
Molsid, France

Recombinant multimeric spike proteins: A promising vaccine against COVID-19
Voxcan Marianne Figl

Marianne Figl
Study Director
Voxcan, France

15h00

Coffee break - B2B - Exhibition Hall - Poster presentation

15h30

Track 4: Innovative vaccines - Lima & Mexico room

Chaired by Sherif Abouelhadid, London school of Hygiene & Tropical Medicine and Lionel Cupillard, Boehringer Ingelheim Animal Health

Evaluation of vaccination strategies against avian influenza in poultry production networks: comparison of the EVACS tool application in several countries
CIRAD/ UMR Astre Claire Hautefeuille

Claire Hautefeuille
Veterinary & epidemiologist
CIRAD/ UMR Astre, France

Current strategic approaches in the evaluation of vaccines as complementary tools for prevention and control of HPAI
Boehringer Ingelheim Teshome Mebatsion

Teshome Mebatsion
Executive Director, Viral Disease Research
Boehringer Ingelheim Santé Animale, France

Multivalent pneumococcal conjugate vaccines: trade-offs of an arms race
LSHTM Anthony Scott

Anthony Scott
Epidemiologist
LSHTM, London
KEMRI-Wellcome Trust, Kenya

Recent advancements in the glycoconjugate vaccines field
GSK Vaccines Francesco Berti

Francesco Berti
Senior Director
GSK Vaccines, Italy

Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate
Osivax Florence Nicolas

Florence Nicolas
Chief Development Officer and Co-Founder
Osivax, France

17h10

Announcement of next year edition

17h20

End of the Congress

ORGANIZERS